Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis

The Pharmacogenomics Journal volume 7, pages 404–407 (2007)Cite this article

Abstract

The folate antagonist methotrexate (MTX) is a drug currently used in the treatment of rheumatoid arthritis (RA). MTX enters the cells through the reduced folate carrier (RFC-1) and is activated to polyglutamates. Previous studies have shown that RFC-1 expression may influence the efficacy of therapy with MTX. The studies suggest that G80A polymorphism in RFC-1 is associated with altered folate/antifolate levels and the subjects carrying homozygous mutant 80AA genotype tend to have higher plasma folate and MTX concentrations and higher erythrocyte polyglutamate levels compared with those with the wild type or heterozygous genotype. It is possible that this polymorphism might influence MTX treatment outcome in patients with RA. In the present study, we examined the association between RFC-1 G80A polymorphism and treatment outcome in patients with RA administered MTX. The study was carried out on 174 patients diagnosed with RA treated with MTX (7.5–15.0 mg weekly) plus low doses of methylprednisone. The RFC-1 80G>A polymorphism (resulting in a histidine-to-arginine substitution at codon 27 of RFC-1) was detected using a polymerase chain reaction-restriction fragment length polymorphism method. The probability of remission of RA symptoms was 3.32-fold higher in carriers of 80AA genotype as compared with patients with 80GG genotype (P=0.021, OR=3.32, 95% CI: 1.26–8.79). The frequency of A allele among MTX responders was 62.1, compared to 47.8% in a group of poor MTX responders (P=0.013, OR=1.78, 95% CI: 1.13–2.81). Moreover, the increase of aminotransferase activity was noted more frequently in carriers of 80AA genotype. The present data suggest that evaluation of RFC-1 gene 80G>A polymorphism may be a useful tool to optimize MTX therapy in patients with RA.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Chan ES, Cronstein BN . Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002; 4: 266–273.

    Article  Google Scholar 

  2. Wang Y, Zhao R, Wang Y, Zhao R, Russell RG, Goldman ID . Localization of the murine reduced folate carrier as assessed by immunohistochemical analysis. Biophys Acta 2001; 1513: 49–54.

    Article  CAS  Google Scholar 

  3. Trippett TM, Bertino JR . Therapeutic strategies targeting proteins that regulate folate and reduced folate transport. J Chemother 1999; 11: 3–10.

    Article  CAS  Google Scholar 

  4. Drori S, Sprecher H, Shemer G, Jansen G, Goldman ID, Assaraf YG . Characterization of a human alternatively spliced truncated reduced folate carrier increasing folate accumulation in parental leukemia cells. Eur J Biochem 2000; 267: 690–702.

    Article  CAS  Google Scholar 

  5. Tolner B, Roy K, Sirotnak FM . Structural analysis of the human RFC-1 gene encoding a folate transporter reveals multiple promoters and alternatively spliced transcripts with 5′ end heterogeneity. Gene 1998; 211: 331–341.

    Article  CAS  Google Scholar 

  6. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004; 50: 2766–2774.

    Article  CAS  Google Scholar 

  7. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Caldwell J et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 2005; 64: 1180–1185.

    Article  CAS  Google Scholar 

  8. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M . Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002; 100: 3832–3834.

    Article  Google Scholar 

  9. Warren MD, Nichols AP, Bender RA . Membrane transport of methotrexate in human lymphoblastoid cells. Cancer Res 1978; 38: 668–671.

    CAS  PubMed  Google Scholar 

  10. Shaw GM, Lammer EJ, Zhu H, Baker MW, Neri E, Finnell RH . Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. Am J Med Genet 2002; 108: 1–6.

    Article  Google Scholar 

  11. Ding BC, Ding BC, Witt TL, Hukku B, Heng H, Zhang L et al. Association of deletions and translocation of the reduced folate carrier gene with profound loss of gene expression in methotrexate-resistant K562 human erythroleukemia cells. Biochem Pharmacol 2001; 61: 665–675.

    Article  CAS  Google Scholar 

  12. Gorlick R, Goker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar M et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 1997; 89: 1013–1018.

    CAS  PubMed  Google Scholar 

  13. Rothem L, Ifergan I, Kaufman Y, Priest DG, Jansen G, Assaraf YG . Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines. Biochem J 2002; 367: 741–750.

    Article  CAS  Google Scholar 

  14. Wong SC, Zhang L, Witt TL, Proefke SA, Bhushan A, Matherly LH . Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier. J Biol Chem 1999; 274: 10388–10394.

    Article  CAS  Google Scholar 

  15. Chango A, Emery-Fillon N, de Courcy GP, Lambert D, Pfister M, Rosenblatt DS et al. A polymorphism (80G>A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 2000; 70: 310–315.

    Article  CAS  Google Scholar 

  16. Morin I, Devlin AM, Leclerc D, Sabbaghian N, Halsted GH, Finnell R et al. Evaluation of genetic veriants in the reduced folate carrier and in glutamate carboxypeptidase II for spina bifida risk. Mol Genet Metab 2003; 79: 197–200.

    Article  CAS  Google Scholar 

  17. Whetstine JR, Gifford AJ, Witt T, Liu XY, Flateley RM, Norris M et al. Single nucleotide polymorphisms in the human reduced folate carrier: characterisation of a high frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin Cancer Res 2001; 7: 3416–3422.

    CAS  PubMed  Google Scholar 

  18. Dervieux T, Kremer J, Lein DO, Capps R, Barham R, Meyer G et al. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 2004; 14: 733–739.

    Article  CAS  Google Scholar 

  19. Rhee MS, Galivan J . Conversion of methotrexate to 7-hydroxymethotrexate and 7-hydroxymethotrexate polyglutamates in cultured rat hepatic cells. Cancer Res 1986; 46: 3793–3797.

    CAS  PubMed  Google Scholar 

  20. Kremer JM, Galivan J, Streckfuss A, Kamen B . Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986; 29: 832–835.

    Article  CAS  Google Scholar 

  21. Wolfe F, O'Dell JR, Kavanaugh A, Wilske K, Pincus T . Evaluating severity and status in rheumatoid arthritis. J Rheumatol 2001; 28: 1453–1462.

    CAS  PubMed  Google Scholar 

  22. Pincus T, Summey JA, Soraci Jr SA, Wallston KA, Hummon NP . Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983; 26: 1346–1353.

    Article  CAS  Google Scholar 

  23. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on outcome measures in rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729–740.

    Article  CAS  Google Scholar 

  24. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–735.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The study was supported by Grant 2P05B11029 for years 2005–2008 from the Ministry of Education and Science (Warsaw, Poland).

Author information

Authors and Affiliations

  1. Department of Pharmacology, Pomeranian Medical University, Szczecin, Poland

    M Drozdzik, T Rudas, A Pawlik, W Gornik & M Kurzawski

  2. Department of Rheumatology, County Hospital, Szczecin, Poland

    M Herczynska

Authors
  1. M Drozdzik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Rudas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Pawlik
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W Gornik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Kurzawski
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Herczynska
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Pawlik.

Additional information

Duality of interest:

None declared.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Drozdzik, M., Rudas, T., Pawlik, A. et al. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J 7, 404–407 (2007). https://doi.org/10.1038/sj.tpj.6500438

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.tpj.6500438

Keywords

This article is cited by

Search

Advanced search

Quick links